Myasthenia gravis
RSS feedIs rituximab useful in ocular myasthenia gravis?
Chinese clinicians report encouraging results regarding the use of rituximab, an anti-CD20 monoclonal antibody, in forms of ocular myasthenia gravis: their pilot study involved 9 adult patients treated between 2023 and 2024 with a low dose of rituximab (200 mg), all of whom were seropositive for acetylcholine receptor (AChR) antibodies, the treatment led to a … [Read more]
Promising results from a CAR-T cell trial in refractory myasthenia gravis
Following the publication of initial success in 2024, a Chinese team has published the results of a multicentre phase I trial that evaluated three different doses of autologous anti-BCMA and anti-CD19 CAR-T cells preceded by lymphodepletion in 18 adults with refractory autoimmune myasthenia gravis: myasthenia had previously been resistant to IV immunoglobulins (67% of participants), … [Read more]
A thymectomy before the generalisation of myasthenia would be preferable in certain patients
While there is still no consensus on the treatment of ocular myasthenia gravis, an Italian team conducted a retrospective study of 174 patients initially diagnosed with an ocular form of myasthenia gravis: 112 underwent thymectomy at the ocular stage of myasthenia gravis, 62 at the generalised stage; 29.3% had thymoma; the stable complete remission rate … [Read more]
An original mode of administration in the treatment of refractory myasthenia gravis
An international consortium of clinicians reports the results of a phase III open-label trial designed to assess the benefit and tolerability of a monoclonal antibody, rozanolixizumab, administered by the patient either by manual pressure or via an infusion pump: 62 adults with generalised myasthenia gravis participated in the trial and were divided into two groups, … [Read more]
A French study on the muscular and cardiac toxicity of immune checkpoint inhibitors
French researchers have investigated the adverse effects of immune checkpoint inhibitors, which are latest-generation anti-cancer drugs: their research focused on the myotoxic and cardiotoxic effects of these molecules, data from the national health data system (SNDS) were screened and analysed for the period 2011-2022, based on 172,000 patients treated in France during this period, between … [Read more]
The added value of artificial intelligence in myasthenia gravis remains to be confirmed
Taiwanese researchers conducted an exhaustive analysis of the literature on artificial intelligence (AI) tools in the context of predictive factors at certain stages of myasthenia gravis: a PRISMA-type approach was used to select 11 studies, which focused on prediction tools based on machine learning algorithms, with particular attention paid to admission to intensive care, length … [Read more]
Three case reports suggest the efficacy of eculizumab in dermatomyositis and myasthenic crisis
Already indicated for refractory forms of myasthenia gravis, eculizumab (Soliris®) has been shown to be effective in two other indications: French clinicians, including experts from the Institute, achieved complete and rapid remission in two patients with dermatomyositis when eculizumab was administered in addition to immunosuppressive therapies. The two young women did not relapse after four … [Read more]
Long-term IV immunoglobulins may reduce the incidence of cancer
According to an analysis of follow-up data from 436 patients with autoimmune myasthenia gravis (MG) and 102 with chronic inflammatory demyelinating polyradiculoneuritis (CIDP), receiving intravenous immunoglobulin (IVIg) as maintenance therapy: is associated with a reduction in the incidence of cancers occurring at least one year after diagnosis. this decrease correlates with the duration of IVIg … [Read more]
Genetic factors may influence the risk of developing myasthenia gravis, as well as its expression
A retrospective study of the records of 281 patients with autoimmune myasthenia gravis followed by an Israeli specialist centre between 2000 and 2022 reveals that: 5.7% of them have a first- or second-degree relative with the same disease, a figure almost identical to that of a previous study (5.6%) conducted in the United States. Compared … [Read more]
A pharmacovigilance study on the use of efgartigimod in myasthenia gravis in the United States
Efgartigimod is one of the new molecules used in refractory forms of myasthenia gravis. Chinese researchers have reviewed the side effects recorded in the Food and Drug Administration (FDA) pharmacovigilance database, which is freely accessible in the United States: the study covered the period from the first quarter of 2022 to the fourth quarter of … [Read more]
